Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3...

Related Keywords

Ukraine ,Switzerland ,Russia ,United States ,Berndt Modig ,International Financial Reporting Standards ,Development Rd Expenses ,National Summit ,European Academy Of Allergy Clinical Immunology ,Bain Capital Life Sciences ,European Union ,International Accounting Standards Board ,Drug Administration ,Exchange Commission ,Chief Executive Officer ,Investigational New Drug ,General Atlantic ,Bio Partners ,Foresite Capital ,Venrock Healthcare Capital ,Angioedema Workshop ,European Academy ,Clinical Immunology ,Hybrid Congress ,Foreign Private Issuer ,International Accounting Standards ,Statement Regarding Forward Looking ,Annual Report ,Markets ,